BioSpace News Archive

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient’s own “killer” T-cells.

According to Precedence Research, the global pulse oximeters market size is estimated to surpass US$ 3.1 billion by 2027 and poised to grow at a CAGR of 6.9% from 2021 to 2027.

According to Precedence Research, the global skin antiseptic products market size is predicted to reach over US$ 379.6 million by 2030 from valued at US$ 215.17 million in 2021 with a CAGR of 6.4% over the forecast period 2021 to 2030.

Conformis, Inc., announced that Gary P. Fischetti has been nominated to stand for election to the Company’s Board of Directors at the Company’s 2022 Annual Meeting of Stockholders, scheduled to be held on May 4, 2022.

AltruBio Inc. announced that president and chief executive officer Judy Chou, Ph.D., will present in-person at BioProcess International U.S. West as a keynote speaker for the plenary session: Ready for the Next Big Thing – Efficient and Sustainable Bioprocess for Global Biomanufacturing Needs.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.

Corbus Pharmaceuticals Holdings, Inc. today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.

Immunome, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of SARS-CoV-2 (COVID-19).

Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals (“Concert”) to acquire a portfolio of Concert’s CNS therapeutics and accompanying intellectual property.